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CASE REPORT
The Role of Laparoscopy in the Diagnosis and
Treatment of Peritoneal Carcinomatosis:
A Case Report
Bayan T. Takizawaa, Eon K. Shin, Louise Masters,
Frederick Lancelle, Vincent Anaf, and Shohreh Shahabi
Department ofObstetrics and Gynecology, Yale University School ofMedicine,
New Haven, Connecticut
A patientpresented with deep venous thrombosis and an elevated CA-125 level, but normalpelvic
ultrasound and abdominal andpelvic CTscans. Laparoscopy revealed diffuse carcinomatosis and
adiagnosis ofstage lIIc, poorlydifferentiatedepithelial ovarian carcinoma was made. Laparoscopy
mayprovide an alternative means ofdiagnosis when conventional imagingfails, andmayfacilitate
theplacement ofcathetersfor subsequent intraperitoneal therapy.
INTRODUCTION
Transcoelomic spread resulting in
peritoneal metastases is a common feature
oftumors within the abdomino-pelvic cav-
ity. However, malignant ascites may notbe
apparent, and this presents a diagnostic
problem for conventional imaging tech-
niques [1]. Laparoscopy can be used to
identify peritoneal carcinomatosis in such
cases. The primary tumor is ovarian in 35
percent ofcases, colonic in 30percent, and
gastric in 10 percent. CA-125 antigen is a
high molecular weight mucin-like glyco-
protein whose serum level is elevated in a
variety of conditions, notably ovarian
epithelial carcinoma. Its increased levels
in several benign conditions suggest it is
not a tumor specific antigen. CA-125 can
be produced by mesothelial cells lining the
adult pleura, pericardium, peritoneum, and
can be considered as a marker of peri-
toneal involvement [2]. Its role has been
well documented for the assessment and
prognosis of ovarian carcinoma and iden-
tification ofrecurrent disease [3].
CASE REPORT
A 59-year-old morbidly obese woman
presented with a primary episode of deep
vein thrombosis. Investigation revealed
thrombosis from the right popliteal vein
extending to the inferior vena cava, but
pelvic ultrasound, CT scan ofthe abdomen
and pelvis, and a chest X-ray were all nor-
mal. Occult neoplasia was suspected and
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tumor markers were requested; the CA-
125 was elevated (11300 IU/1; N < 35
IU/l) and the CA-15.3 was elevated (460
IU/l; N < 60 IU/1). Work up for breast, GI,
and pancreatic tumors was negative.
A diagnostic laparoscopy with biopsy
demonstrated extensive peritoneal carci-
nomatosis, ovarian in nature, involving the
pelvic organs, both paracolic gutters, the
greater omentum, and the diaphragm. The
procedure was then converted to a laparo-
tomy and a hysterectomy, bilateral salpin-
go-oophorectomy, lymphadenectomy,
omentectomy, and tumor debulking were
performed. The histology confirmed a
poorly differentiated ovarian carcinoma,
stage IlIc.
Surgery was followed by treatment
with chemotherapy. First chemotherapy
was cisplatin (Platinol, Bristol-Myers
Squibb) (50 mg/m2, days 1 to 3) and
cyclophosphamide (Endoxan, ASTAMed-
ica) (600 mg/m2, day 1). This regimen was
discontinued after three cycles forplateau-
ing CA-125 levels (31,000 IU/l before
treatment and 27,200 IU/l after treatment).
Second line treatment was cyclophos-
phamide with paclitaxel (Taxol, Bristol-
Myers Squibb) (135 mg/m2) but progres-
sion of disease was suspected after three
cycles with rising CA-125 levels, thus
treatment was changed to topotecan
(Hycamtin, Smithkline Beecham) (1.25
mg/m2, days 1 to 5). A CT scan during the
course of topotecan showed the presence
of ascites and thickened folds of peri-
toneum. The patient was admitted before
her fifth cycle of topotecan for treatment
of a bowel obstruction. She underwent
laparoscopy, which revealed continued
diffuse peritoneal carcinomatosis. The
laparoscope was then used to position an
intraperitoneal catheter through which
chemotherapy was administered forpallia-
tive therapy. The patient died one month
later.
DISCUSSION
Peritoneal carcinomatosis compli-
cates approximately 35 percent of ovarian
carcinomas. Ovarian cancer is the second
most common gynecological malignancy
in the United States, with an annual inci-
dence ofroughly 25,000 and annual death
rate of nearly 15,000. Its prognosis has
improved slightly over the past two
decades, although in two-thirds ofpatients
the disease has already spread beyond the
pelvis at the time of presentation. The
diagnosis of ovarian cancer is often mis-
managed because of understaging [4].
Young et al. [5] described a series of 100
patients in which 31 were understaged at
the time oforiginal diagnosis, 23 ofwhich
were stage III.
Ultrasound has been found useful in
the diagnosis ofperitoneal carcinomatosis,
but its sensitivity in detecting seedling
implants is highly variable, ranging from 8
to 63 percent [1]. CT scanning has similar
limitations, specifically when scanning the
pelvis. MRI scanners have a sensitivity of
82 percent for recurrent disease at the pri-
mary site when the tumor mass is greater
than 2 cm in diameter, but this drops to 35
percent sensitivity for smaller lesions.
Sensitivity for peritoneal deposits is poor,
with lesions of 3 cm diameter often
missed. Clearly another method ofdiagno-
sis is indicated.
Laparoscopy can provide a sensitive
means of diagnosing peritoneal carcino-
matosis. It is preferable to laparotomy in
most cases because it is safer for the
patient. Post-operative complications of
laparotomy include wound infections, pro-
longed ileus, small intestinal obstructions,
and intestinal injury. Improvements in
laparoscopic techniques have indeed made
laparoscopy a safer and viable option to
laparotomy. It has been shown to have a
positive predictive value of 100 percent
and a negative predictive value of 86 per-
cent [6]. However, post-operative adhe-
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laparoscopy more difficult to identify
residual disease, in which case conversion
to open laparotomy is indicated.
Laparoscopy may also have a role in sec-
ond-look procedures, though these have
historically been controversial [7]. It is
useful in reviewing the effectiveness of
chemotherapy by allowing directed biop-
sies to be taken and in vitro sensitivities to
be assessed. Chemotherapy can be admin-
istered via intraperitoneal catheters or
implant capsules, and can be positioned
accurately through the laparoscope at the
same time as the second look assessment.
Intraperitoneal chemotherapy, popu-
lar in the 1950s [8], has again found a role
in patients with persistent intraperitoneal
tumors after debulking surgery and
aggressive chemotherapy with first- and
second-line drugs. Larger volumes offluid
(1500-2000 ml) are now being used to dis-
tribute the drugs more evenly [9], and
safer and more effective drug delivery sys-
tems have been developed [10]. These two
advances have made intraperitoneal
chemotherapy more beneficial, and hence
popular again. Studies have shown that it
is most effective with small deposits no
greater than 2 mm in diameter [11]. This
method yields response rates of up to 55
percent, ofwhich 30percent result in com-
plete remission. These results that can be
achieved even when a tumor has shown
resistance to intravenous chemotherapeu-
tic agents.
The role of serum antigen CA-125 as
a markerin monitoring the management of
ovarian carcinoma has been extensively
studied and several clinical research teams
concur on its predictive value [12]. Indeed,
there does seem to be a correlation
between the rate of decline of serum CA-
125 and the prognosis of disease [13].
However, its value in screening programs
has yet to be confirmed. Although a
strongly elevated CA-125 level indicates a
high likelihood ofovarian carcinoma, as in
this case, moderately elevated levels can
be present in benign conditions such as
liver disease, pancreatitis, peritonitis,
endometriosis, benign ovarian tumors,
benign ascites, and pregnancy. The simul-
taneous use ofother markers such as CEA,
CA-19, and CA-15.3, which by them-
selves are not very specific, may, in con-
junction with CA-125, improve the diag-
nostic accuracy ofthe study [2].
CONCLUSION
Imaging techniques have been disap-
pointing in the diagnosis and follow-up of
peritoneal metastases, especially in diffuse
peritoneal carcinomatosis. Conversely,
laparoscopy provides a more accurate
assessment with the advantage of direct
vision, which allows directed biopsies to
be taken and, when appropriate, the posi-
tioning of peritoneal chemotherapy deliv-
ery systems. The sensitivity of
laparoscopy has been shown to be 100 per-
cent, thus a positive finding would clearly
indicate the need for laparotomy and pos-
sible tumor debulking or salvage
chemotherapy. As laparoscopic techniques
improve, the diagnosis of difficult cases
complicated by severe adhesions will be
made possible by laparoscopy, saving
patients from the often complicated post-
operative course oflaparotomy.
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